about
Novel Therapies for Eosinophilic DisordersInnate immunity in diseaseRe-defining the unique roles for eosinophils in allergic respiratory inflammationAnti-IL5 therapy for asthma and beyondInterleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needsMepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Biologic therapies targeting eosinophils: current status and future prospects.Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic ColitisOdd couple: The unexpected partnership of glucocorticoid hormones and cysteinyl-leukotrienes in the extrinsic regulation of murine bone-marrow eosinopoiesis.Novel biomarkers for asthma stratification and personalized therapy.EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.Eosinophilic Skin Diseases: A Comprehensive Review.Treatment of severe asthma: entering the era of targeted therapy.Role of Eosinophil Granulocytes in Allergic Airway Inflammation Endotypes.The safety of monoclonal antibodies in asthma.Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.Regulatory Eosinophils Suppress T Cells Partly through Galectin-10.Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.Newly divided eosinophils limit ozone-induced airway hyperreactivity in nonsensitized guinea pigs.The role of interleukin 5 in asthma.Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease.The Eosinophil: for better or worse, in sickness and in health.Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.
P2860
Q26799600-E456276B-4BD0-4C42-A0F9-015B90255C11Q26825435-A0474E3F-C765-4AE8-9F72-6CA2B2BC7BC3Q26828515-73AE3E51-0B54-4A0D-A456-34A3061C95D6Q26866943-A1A81F7E-190C-4E13-84C3-65C318BD7DFFQ28067081-9178DE4F-F8DD-44B2-86E2-AA1B28C47ACBQ34544937-52505955-F6DD-4867-A6B1-F92E5112E869Q35565533-4DD19FCC-5E88-4695-856E-C06FC6099A95Q35898996-81349727-77F3-44EC-93B9-69B0332104F9Q36297766-4B01F9D1-B8FA-43B5-86BA-4604A049E67EQ38283811-78AD1EE9-557B-405C-A3FF-B2F60B5BB800Q38394577-13ECAC97-9A55-4CE7-B8E4-0F7DC9C0F844Q38422236-6D2E16AF-3937-46EE-B4B2-6AC8AE01325DQ38578918-9EE7630A-58F2-4B68-A48D-2E370710DD33Q38831891-049FD5EA-0034-45CA-813D-1771675636D0Q38842153-942BD687-928E-4C09-98A8-7651F89D0536Q39189229-ED3182DA-28C3-42BB-B15B-023074A0281DQ40208709-4A05DB74-8819-436F-B892-3D71A56E5F66Q41605623-6685B854-9604-4E0E-B89B-923341492127Q47960048-4F245924-86C2-451B-96F1-A174E662FC5CQ51483829-8118166D-145D-47A6-ABD5-AE3C70F6600BQ52571066-448E386B-ECC3-47DD-BC52-AF656B9E64A7Q52719312-F5AB8E7E-9045-471B-9B89-5247E7D14990Q52729256-CFA66ED4-D716-45AE-AF11-90D02BCE62AAQ55115543-56B28ED1-5642-4386-B546-F085CAD92F74
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The consequences of not having eosinophils.
@en
The consequences of not having eosinophils.
@nl
type
label
The consequences of not having eosinophils.
@en
The consequences of not having eosinophils.
@nl
prefLabel
The consequences of not having eosinophils.
@en
The consequences of not having eosinophils.
@nl
P2093
P2860
P356
P1433
P1476
The consequences of not having eosinophils
@en
P2093
P2860
P304
P356
10.1111/ALL.12169
P50
P577
2013-06-06T00:00:00Z